Wide Ranks

CARA

Cara Therapeutics, Inc.

0.2881

Top Statistics
Market Cap 15 M Forward PE -0.3920 Revenue Growth -85.70 %
Current Ratio 4.59 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.0730 Enterprise / Revenue 0.6920 Price To Sales Trailing12 Months 1.44
Profitability
Profit Margins 0.00 % Operating Margins -1636.12 %
Balance Sheet
Total Cash 56 M Total Cash Per Share 1.03 Total Debt 47 M
Total Debt To Equity 406.66 Current Ratio 4.59 Book Value Per Share 1.05
All Measures
Short Ratio 220.00 % Message Board Id finmb_23340079 Shares Short Prior Month 832171
Return On Equity -1.84 City Stamford Uuid 2959e4f9-c48b-308c-8431-9b84f96c60e5
Previous Close 0.2900 First Trade Date Epoch Utc 1 B Book Value 1.05
Beta 0.6810 Total Debt 47 M Volume 323743
Price To Book 0.2749 Fifty Two Week Low 0.2400 Total Cash Per Share 1.03
Total Revenue 10 M Shares Short Previous Month Date 1 B Target Median Price 1.01
Audit Risk 2 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -1636.12 % Target Mean Price 1.66 Net Income To Common -111081000
Short Percent Of Float 0.0200 Implied Shares Outstanding 54 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 529540 Average Volume10days 529540
Total Cash 56 M Next Fiscal Year End 1 B Revenue Per Share 0.2020
Held Percent Insiders 0.1574 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 7 Regular Market Previous Close 0.2900
Target Low Price 1.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.2894
Open 0.2850 Free Cashflow -47503000 State CT
Dividend Yield 0.00 % Return On Assets -0.6343 Time Zone Short Name EST
Board Risk 4 Trailing Eps -1.75 Day Low 0.2850
Address1 400 Atlantic Street Shares Outstanding 54 M Compensation Risk 10
Price Hint 4 Target High Price 3.60 Website https://www.caratherapeutics.com
52 Week Change -0.7022 Average Volume 515956 Forward Eps -0.7700
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 420.40 %
Is_sp_500 False Regular Market Day High 0.2980 Profit Margins 0.00 %
Debt To Equity 406.66 Fifty Two Week High 1.31 Day High 0.2980
Shares Short 942535 Regular Market Open 0.2850 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 0.6920 Revenue Growth -85.70 %
Shares Percent Shares Out 0.0172 Operating Cashflow -79905000 Currency USD
Time Zone Full Name America/New_York Market Cap 15 M Is_nasdaq_100 False
Zip 06901 Quote Type EQUITY Industry Biotechnology
Long Name Cara Therapeutics, Inc. Overall Risk 8 Regular Market Day Low 0.2850
Held Percent Institutions 0.2816 Current Price 0.2881 Address2 Suite 500
Enterprise To Ebitda -0.0730 Financial Currency USD Current Ratio 4.59
Industry Disp Biotechnology Number Of Analyst Opinions 4 Country United States
Float Shares 46 M Two Hundred Day Average 0.5052 Governance Epoch Date 1 B
Enterprise Value 7 M Price To Sales Trailing12 Months 1.44 Forward PE -0.3920
Regular Market Volume 323743 Ebitda -104724000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States.

The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.

It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica.

The company has license agreements with Maruishi Pharmaceutical Co.

, Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd.

development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea.

Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.